186 related articles for article (PubMed ID: 33387703)
1. Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate.
Cascio MJ; Whitley EM; Sahay B; Cortes-Hinojosa G; Chang LJ; Cowart J; Salute M; Sayour E; Dark M; Sandoval Z; Mitchell DA; Milner RJ
Vet Immunol Immunopathol; 2021 Feb; 232():110169. PubMed ID: 33387703
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
Toda Y; Kohashi K; Yamada Y; Yoshimoto M; Ishihara S; Ito Y; Iwasaki T; Yamamoto H; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2607-2620. PubMed ID: 32388585
[TBL] [Abstract][Full Text] [Related]
3. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
[TBL] [Abstract][Full Text] [Related]
4. Programmed cell death ligand 1 expression in osteosarcoma.
Shen JK; Cote GM; Choy E; Yang P; Harmon D; Schwab J; Nielsen GP; Chebib I; Ferrone S; Wang X; Wang Y; Mankin H; Hornicek FJ; Duan Z
Cancer Immunol Res; 2014 Jul; 2(7):690-698. PubMed ID: 24866169
[TBL] [Abstract][Full Text] [Related]
5. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma.
Koirala P; Roth ME; Gill J; Piperdi S; Chinai JM; Geller DS; Hoang BH; Park A; Fremed MA; Zang X; Gorlick R
Sci Rep; 2016 Jul; 6():30093. PubMed ID: 27456063
[TBL] [Abstract][Full Text] [Related]
6. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
[TBL] [Abstract][Full Text] [Related]
7. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032
[TBL] [Abstract][Full Text] [Related]
8. Cloning and expression of canine CD25 for validation of an anti-human CD25 antibody to compare T regulatory lymphocytes in healthy dogs and dogs with osteosarcoma.
Rissetto KC; Rindt H; Selting KA; Villamil JA; Henry CJ; Reinero CR
Vet Immunol Immunopathol; 2010 May; 135(1-2):137-145. PubMed ID: 20197202
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
Maekawa N; Konnai S; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Takagi S; Kagawa Y; Nakajima C; Suzuki Y; Kato Y; Murata S; Ohashi K
PLoS One; 2016; 11(6):e0157176. PubMed ID: 27276060
[TBL] [Abstract][Full Text] [Related]
10. Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma.
Withers SS; York D; Choi JW; Woolard KD; Laufer-Amorim R; Sparger EE; Burton JH; McSorley SJ; Monjazeb AM; Murphy WJ; Canter RJ; Rebhun RB
Vet Comp Oncol; 2019 Sep; 17(3):242-252. PubMed ID: 30684301
[TBL] [Abstract][Full Text] [Related]
11. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
12. Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype.
Kostine M; Cleven AH; de Miranda NF; Italiano A; Cleton-Jansen AM; Bovée JV
Mod Pathol; 2016 Sep; 29(9):1028-37. PubMed ID: 27312065
[TBL] [Abstract][Full Text] [Related]
13. Comparative Immunology and Immunotherapy of Canine Osteosarcoma.
Mason NJ
Adv Exp Med Biol; 2020; 1258():199-221. PubMed ID: 32767244
[TBL] [Abstract][Full Text] [Related]
14. Various checkpoint molecules, and tumor-infiltrating lymphocytes in common pediatric solid tumors: Possibilities for novel immunotherapy.
Mochizuki K; Kawana S; Yamada S; Muramatsu M; Sano H; Kobayashi S; Ohara Y; Takahashi N; Hakozaki M; Yamada H; Hashimoto Y; Kikuta A
Pediatr Hematol Oncol; 2019 Feb; 36(1):17-27. PubMed ID: 30870043
[TBL] [Abstract][Full Text] [Related]
15. HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors.
Dailey DD; Anfinsen KP; Pfaff LE; Ehrhart EJ; Charles JB; Bønsdorff TB; Thamm DH; Powers BE; Jonasdottir TJ; Duval DL
BMC Vet Res; 2013 Jul; 9():130. PubMed ID: 23816051
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma.
Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S
Pathol Res Pract; 1998; 194(10):679-84. PubMed ID: 9820863
[TBL] [Abstract][Full Text] [Related]
17. Pre- and postoperative studies of in vitro cell-mediated reactivity in canine osteosarcoma.
Bech-Nielsen S; Reif JS; Brodey RS
Am J Vet Res; 1978 Jan; 39(1):87-93. PubMed ID: 272858
[No Abstract] [Full Text] [Related]
18. The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
Ren S; Tian Q; Amar N; Yu H; Rivard CJ; Caldwell C; Ng TL; Tu M; Liu Y; Gao D; Ellison K; Suda K; Rozeboom L; Rivalland G; Mitchell P; Zhou C; Hirsch FR
Lung Cancer; 2018 Nov; 125():115-120. PubMed ID: 30429008
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint molecule expression by B and T cell lymphomas in dogs.
Hartley G; Elmslie R; Dow S; Guth A
Vet Comp Oncol; 2018 Sep; 16(3):352-360. PubMed ID: 29380929
[TBL] [Abstract][Full Text] [Related]
20. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Park JA; Cheung NV
J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
